MedCityNews – Serial Entrepreneur to Receive Award – October 31, 2011
MedCityNews – Serial Entrepreneur to Receive Award – October 31, 2011 Article >>>>>
News Articles
Scientific Presentations
Mechanism of Action of Posiphen: from Model to Human
Speaker: Maria L. Maccecchini Presentation, January 2011. WCBR, More >>>>>
Press Release
Presentation at NewsMakers
QR Pharma, Inc. to Present Corporate Update at 23rd Annual BioCentury NewsMakers Conference –One of Fourteen Private Companies Selected to Present– Berwyn, PA, September 9, 2016 — QR Pharma, Inc., a privately held Phase 2 biopharmaceutical company developing novel therapies for the treatment of Alzheimer’s, Parkinson’s and other neurodegenerative diseases, today announced that Maria Maccecchini,
Scientific Presentations
Posiphen® Treatment is Able to Reduce APP Levels in Ta65Dn Mouse Model of Down Syndrome
Poster, 2008. ICAD, More>>>>>
Press Release
Posiphen® Restores Brain Function, Cognition and Memory in Transgenic Alzheimer Mice
Berwyn, PA, October 22, 2012: QR Pharma, Inc. (QR), a clinical stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of Alzheimer’s disease(AD), Parkinson’s disease (PD) and other neurodegenerative disorders, announced today that Dr. Maria Maccecchini, CEO, will be presenting new data on its lead compound “Posiphen® Recovers Memory, Learning
Scientific Presentations
Posiphen Human Clinical Data
Maria L. Maccecchini, M. Murphy, N. Skuban, Debomoy K. Lahiri, Nigel H. Greig Poster, July 2010. ICAD, More >>>>>
Scientific Presentations
Posiphen Human Biomarker Data
H.W. Holloway, N.H. Greig, V. John, C. Pan, M. Murphy, MY Chang, M.L. Maccecchini Poster, January 2011. WCBR, More >>>>>
News Articles
BioCentury – QR: Power of positivity – May 30, 2011
BioCentury – QR: Power of positivity – May 30, 2011
Press Release
Ben Franklin Technology Partners Invests $110,000 in QR Pharma
Berwyn, PA, April 3, 2012 QR Pharma, Inc.(QR), a clinical-stage specialty pharmaceutical company committed to developing novel approaches for the treatment of Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative disorders, announced today the receipt of a $110,000 investment from Ben Franklin Technology Partners of Southeastern Pennsylvania (BFTP). This funding is in addition to